COMP <GO>
LGND vs MRK // REVENUE GROWTH (YOY)
Ligand Pharmaceuticals Incorporated (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: LGND 6
— MRK 9
▲ REVENUE GROWTH (YOY) LEADER: LGND
LAST: $322.75 (+1.71%) • MKT CAP: $6.33B
revenue-growth
60.40%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LGND VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LGND | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.00% | 20.70% | -17.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 15.3x | +79.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 0.77% | 3.42% | -2.65 | MRK | /fcf-yield <GO> |
| Operating Margin | 15.30% | 34.30% | -19.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 46.40% | 28.10% | +18.30 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 60.40% | 1.30% | +59.10 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.40 | 5.19 | +3.21 | LGND | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LGND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.4 | 56.9 | +6.53 | LGND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.92 | +0.15 | LGND | /macro-sensitivity <GO> |
| Forward P/E Multiple | 42.7x | 18.4x | +24.30 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.33B | $361.02B | -$354.70B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LGND REV | MRK REV | LGND GROSS % | MRK GROSS % | LGND FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $268.1M | $65.01B | 44.0% | 74.8% | $48.9M | $12.36B |
| FY 2024 | $167.1M | $64.17B | 44.0% | 76.3% | $95.2M | $18.10B |
| FY 2023 | $131.3M | $60.12B | 44.0% | 44.0% | $43.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LGND // BETA 1.07
MRK // BETA 0.92